Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial

Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial

[ad_1]

Introduction

Azithromycin is an orally active synthetic macrolide antibiotic with a wide range of antibacterial, anti-inflammatory, and antiviral properties.

Azithromycin in viral infections.